Use search to browse all 100+ peptides
Mounjaro, Zepbound, LY3298176
A dual GLP-1 and GIP receptor agonist used for type 2 diabetes and obesity, enhancing insulin secretion, suppressing glucagon, and promoting weight loss.
Eason. Kieran K; Feeney. Claire C; Killeen. Tim T
A couple where the woman took tirzepatide lost over 30% of her weight, and her partner, who didn’t take the drug, also lost 13% weight, dropped his HbA1c from 9.5% to 6.1% and cut insulin use by about 70%, likely because the household’s eating and activity habits changed together.
Kim. Heeseong H; Kim. Seung Woo SW; Choi. Cheoljun C; Joo. SungUg S; Kim. Gibae G; Kim. Minjae M; Ya...
In obese mice, both the experimental drug LJ-4378 and the approved drug tirzepatide helped lose weight, improve blood sugar control, and boost energy use. LJ-4378 did this without cutting food intake and, after stopping the drug, mice regained far less weight than those that stopped tirzepatide, keeping many of the metabolic benefits. This suggests a new way to keep weight off after a treatment ends, though LJ-4378 isn’t available for people yet.
Crisafulli. Salvatore S; Alkabbani. Wajd W; Paik. Julie M JM; Bykov. Katsiaryna K; Tavakkoli. Ali A;...
A big real‑world study looked at gut‑related side effects of three popular diabetes drugs—dulaglutide, semaglutide, and tirzepatide—and found they all have about the same risk of serious stomach or intestinal problems.
Natale. Raffaele R; Morena. Annadora A; Capece. Luca Maria LM; Donnarumma. Sofia S; Pagano. Ermenegi...
A 66‑year‑old woman on a mechanical heart valve started tirzepatide for obesity and, after 10 days, her blood thinner (warfarin) levels (INR) dropped unexpectedly. The drop wasn’t due to diet changes and was likely because tirzepatide slows stomach emptying, affecting how warfarin is absorbed. Doctors had to raise her warfarin dose and keep a closer eye on INR for several weeks.
Gasoyan. Hamlet H; Butsch. W Scott WS; Casacchia. Nicholas J NJ; Schulte. Rebecca R; Criswell. Victo...
A recent study looked at why people stopped using the weight‑loss drugs semaglutide or tirzepatide within a year. Almost half quit because the medication was too expensive or not covered by insurance, about 15% stopped because they couldn’t handle the side effects, and roughly 12% couldn’t get the drug due to shortages. A few switched to compounded versions or stopped because they weren’t losing enough weight.
Courtney. Lindsay A LA; Clements. Jennifer N JN; Isaacs. Diana D; Pitlick. Jamie M JM; Reece. Sara M...
This article says that while a few small studies suggest compounded tirzepatide might help, the drug isn’t FDA‑approved, so there are legal and safety worries. Doctors should try to get patients the approved version, but if someone uses a compounded version, they need to pick a trustworthy pharmacy and watch for any problems.
Thomas. Oliver O; Coulson. James Michael JM
A small pilot study found that most emergency department visits among people taking GLP‑1 or GIP/GLP‑1 drugs, especially tirzepatide, were actually caused by the medication itself. The risk was higher in the poorest and richest neighborhoods and in folks who also have depression. This suggests you should watch for side‑effects and be ready to manage them, especially if you have mood issues or live in a high‑risk area.
Ameer. Fatima F; Villacres. Nicole Yañez NY; Bustos. Daniel D; Shah. Pari C PC; Appah. Noble N;...
Tirzepatide, a drug that hits both GLP‑1 and GIP receptors, helps people lose weight and improve blood sugar, but it can also cause stomach upset and mood changes, so you need to watch how you feel and combine it with a good diet, exercise, and mental‑health support.
Scarpa. Emanuele-Salvatore ES; Amatori. Stefano S; Caprioli. Giovanni G; Maggi. Filippo F; Moroncini...
This review says that tirzepatide already helps people lose weight and improve insulin resistance, and that many plant compounds called flavonoids can also block fat cell formation and reduce inflammation. Putting flavonoid‑rich foods or supplements together with tirzepatide might make the drug work even better, but the idea is still theoretical and needs more testing.
Alsuwailem. Omar A OA; Alanazi. Rawan R; Almutairi. Hessa M HM; Asiree. Rayan H RH; Almutairi. Wasan...
A recent systematic review looked at whether GLP‑1 drugs like tirzepatide cause hair loss. It found mixed results – some studies reported people actually grew hair back, while others saw hair thinning or loss. Because the data are conflicting, it’s a reminder to watch your hair health if you’re using these drugs, but there’s no clear rule yet on how to prevent or treat any effect.
Afshari. Somaye S; Khosravi. Majid M; Zamandi. Mahmood M; Rezapour. Aziz A; Hadian. Marziye M; Soure...
The review looked at how much anti‑obesity drugs cost compared to the health benefits they give. It found that tirzepatide works really well for weight loss, but it’s also pricey, so whether it’s worth it depends on your budget and situation. Other drugs like semaglutide give good results for less money, while cheaper options like phentermine‑topiramate or orlistat are more affordable but less powerful.
Reis-Barbosa. Pedro H PH; Cardoso. Luiz Eduardo M LEM; Mandarim-de-Lacerda. Carlos A CA
In a mouse study that mimics obesity, diabetes, and menopause, tirzepatide (a drug already used for weight loss and diabetes) helped keep the tiny blood‑vessel‑rich structures in the pancreas healthy. It lowered scar‑forming proteins and enzymes that break down tissue, boosted factors that support blood‑vessel growth, and reduced harmful amyloid signals, overall protecting the pancreas from damage.
Xie. Xingmiao X; Yang. Shuiyuan S; Deng. Shuzhen S; Liu. Yuying Y; Xu. Zhibin Z; He. Binghong B
A big review of 48 trials (27,729 people) found that the new drug tirzepatide causes more stomach upset—especially nausea and diarrhea—than other GLP‑1 drugs used for type‑2 diabetes. Other drugs like dulaglutide and lixisenatide were easier on the gut, while exenatide caused more vomiting and semaglutide gave more diarrhea. This info helps people who experiment with these peptides know which ones might be harder on their digestion.
Ognard. Julien J; Alipour Khabir. Sevda S; Ghozy. Sherief S; El Hajj. Gerard G; Kallmes. Kevin M KM;...
A review of nine studies shows that drugs like tirzepatide, which activate the GLP‑1 receptor, can quickly lower brain pressure, cut headaches, and help people lose weight in a condition called idiopathic intracranial hypertension. The benefits seem real and side effects are mostly mild stomach upset, but the evidence is still early and mostly from small or retrospective studies.
Weber. Luisa L; Hashemnia Sharbabaki. Maryam M; Fuchs. Benedikt B; Alberton. Paolo P; Giunta. Riccar...
Studies in lab dishes show that drugs that activate the GLP‑1 receptor—like those used for diabetes and weight loss—can make human stem cells grow more and turn into bone cells while stopping them from becoming fat cells. They also protect these cells from inflammation and death, even in diabetic‑like conditions. However, all this work is done in vitro, so we don’t yet know how it translates to real people.
Shestakova. M V MV; Bashlykova. R O RO
The paper says that drugs that mimic gut hormones, especially tirzepatide which hits two hormone receptors at once, are looking very promising for losing weight and controlling blood sugar in diabetes. It also mentions that even newer drugs that hit three or four gut hormone receptors are being developed and could be even more powerful.
Horn. Deborah B DB; Aronne. Louis J LJ; Wharton. Sean S; Bays. Harold E HE; Gomez-Valderas. Elisa E;...
The SURMOUNT-MAINTAIN study is testing if people who have already lost weight on the highest tolerated dose of tirzepatide can keep that loss by either staying on the same dose, dropping to a lower dose, or stopping the drug altogether. It’s a 52‑week, double‑blind trial with adults who have obesity but not diabetes, and it will measure how much of the original weight loss is kept after a year. The results will tell whether a lower maintenance dose can still work, which could help people plan long‑term use of tirzepatide for weight control.
Colorado. Maria M; Gomez Miranda. Jose J; Arias-Morales. Carlos E CE
The paper reports three people who felt heart‑palpitations, joint‑muscle aches, and headaches after starting tirzepide, a new weight‑loss drug, suggesting these side‑effects may be more common than thought.
Huston. Jessica J; Orey. Dontia D; Ashchi. Andrew A; Lachapelle. Andrea Ashchi AA; Genovese. Ariana...
The review says tirzepatide, a drug that activates both GLP‑1 and GIP receptors, looks promising for people with type‑2 diabetes and obesity because it may lower or at least not increase heart‑related risks, similar to other GLP‑1 drugs that are already known to protect the heart.
Shah. Islam I; Sennik. Devesh D; Veettil. Fahas Ali Vattiyam FAV
A 63‑year‑old woman started tirzepatide for weight loss and, within four days, suffered seizures caused by severe low blood sodium (hyponatraemia). Tests showed she had SIADH, a condition where the body holds onto too much water, and no other cause was found. Stopping tirzepatide and restricting fluids fixed her sodium levels and she recovered fully.